DUBLIN, June 24, 2021 /PRNewswire/ -- Theravance
Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a
diversified biopharmaceutical company primarily focused on the
discovery, development and commercialization of organ-selective
medicines, announced today the pricing of its underwritten public
offering of 6,700,000 ordinary shares at a price to the public of
$15.00 per share. The gross
proceeds to Theravance Biopharma from the offering are
expected to be $100.5 million, before
deducting underwriting discounts and commissions and estimated
offering expenses. In addition, Theravance Biopharma has
granted the underwriters a 30-day option to purchase up to an
additional 1,005,000 ordinary shares at the public offering price,
less underwriting discounts and commissions. The offering is
expected to close on June 29, 2021,
subject to customary closing conditions.
SVB Leerink and Evercore ISI acted as joint lead bookrunners.
Credit Suisse also acted as a bookrunner for the offering. H.C.
Wainwright & Co. acted as lead-manager for the offering.
A shelf registration statement (including a base prospectus)
relating to the shares was filed with the SEC and is effective. A
preliminary prospectus supplement related to the offering has been
filed with the SEC and a final prospectus supplement and
accompanying prospectus related to the offering will be filed with
the SEC and will be available on the SEC's website located at
http://www.sec.gov. Copies of the final prospectus supplement
and the accompanying prospectus relating to this offering, when
available, may be obtained from SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at
1-800-808-7525 ext. 6105, or by email at syndicate@svbleerink.com;
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 36th Floor, New York,
NY 10055, or by telephone at (888) 474 0200, or by email at
ecm.prospectus@evercore.com; or Credit Suisse Securities
(USA) LLC, Attention: Prospectus
Department, 6933 Louis Stephens Drive, Raleigh, NC 27560, or by telephone at
1-800-221-1037, or by e-mail at
usa.prospectus@credit-suisse.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995: This announcement
contains "forward-looking statements" such as those,
among others, relating to Theravance Biopharma's expectations
regarding the completion of the proposed public offering. These
statements are subject to significant risks and uncertainties;
actual results could differ materially from those projected and
Theravance Biopharma cautions investors not to place undue reliance
on the forward-looking statements contained in this release. These
risks and uncertainties include, without limitation, risks and
uncertainties related to the satisfaction of customary closing
conditions related to the proposed public offering. There can
be no assurance that Theravance Biopharma will be able to complete
the public offering on the anticipated terms, or at all. Risks and
uncertainties relating to Theravance Biopharma and its business can
be found in the "Risk Factors" section of Theravance Biopharma's
Form 10-Q, filed with the SEC on May 6,
2021, in Theravance Biopharma's other filings with the SEC
and in the preliminary prospectus supplement relating to the
proposed offering filed with the SEC on June
24, 2021. Theravance Biopharma undertakes no duty or
obligation to update any forward-looking statements contained in
this release as a result of new information, future events or
changes in Theravance Biopharma's expectations.
Contact: Gail Cohen
Corporate Communications
917-214-6603
investor.relations@theravance.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/theravance-biopharma-inc-announces-pricing-of-public-offering-of-ordinary-shares-301319945.html
SOURCE Theravance Biopharma, Inc.